All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub was pleased to speak to Claire Harrison, Guy’s and St Thomas’ NHS Foundation Trust, London, UK. We asked, What is the rationale for using bromodomain and extraterminal (BET) inhibitors to treat myelofibrosis?
What is the rationale for using BET inhibitors to treat myelofibrosis?
Harrison opens by discussing the unmet needs for patients with myelofibrosis who are unresponsive or intolerant to typical treatments such as ruxolitinib. The clinical applications of BET inhibitors are summarized, including the targeting of nuclear factor kappa B pathways, megakaryopoiesis, and erythropoiesis. Harrison concludes by highlighting the recent advancements in BET inhibitors for this indication and the latest updates published at the ASH Annual Meeting and Exposition.
ASH 2022 abstracts: What’s hot in MPN?
To help navigate the exciting content being presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub Steering Committee have provided their recommendations for the...
How to understand and manage cytopenic myelofibrosis?
During the Texas MPN Workshop (TMW) 2022, the MPN Hub was pleased to speak to Prithviraj Bose, MD Anderson Cancer Center, Houston, US. We asked about understanding and managing cytopenic...
Subscribe to get the best content related to MPN delivered to your inbox